Abstract
A newly developed polysulfone hemofilter [FS-104, Toray Industries, Inc.] was clinically evaluated in 37 patients with chronic renal failure under renal replacement therapy. Totally 75 sessions of hemofiltration (HF) was performed under 210ml/min, 69ml/min and 15L (about 30% of dry weight) of blood flow rate (QB), ultrafiltration rate (QF) and substitution volume, respectively. TMP significantly increased in the course of HF and stabilized around 200mmHg after 3 hours of HF without any significant reduction of QF. Reduction rates of BUN, Cr, UA and β2M showed 42.5, 45.6, 57.3 and 73.5%, respectively. There were no significant differences in sieving coefficients for BUN, Cr, UA and β2M between 1 and 4 hours after the start of HF. About 180 mg of β2M was eliminated into ultrafiltrates, however, protein loss remained below 300mg per each treatment. Mild but significant leukopenia was observed at 15min after the start of HF (80% of pre-value, p<0.01). There was mild increase in plasma C3a at the outlet compared to the inlet blood of hemofilter without any significant changes in systemic plasma C3a concentration. From these results, it is concluded that FS-104 has not only effective removal capacity for uremic accumulates, in particular low molecular weight protein fractions, but also the excellent biocompatibility.
